This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benjamin, D. K.
Right arrow Articles by Walsh, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benjamin, D. K., Jr.
Right arrow Articles by Walsh, T. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2006, p. 632-638, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.632-638.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Safety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections

Daniel K. Benjamin Jr.,1 Timothy Driscoll,1 Nita L. Seibel,2 Corina E. Gonzalez,3 Maureen M. Roden,4 Rahki Kilaru,1 Kay Clark,5 James A. Dowell,5 Jennifer Schranz,5 and Thomas J. Walsh4*

Department of Pediatrics and Duke Clinical Research Institute, Duke University, Durham, North Carolina,1 Children's National Medical Center, Washington, D.C.,2 Georgetown University, Washington, D.C.,3 National Cancer Institute, Bethesda, Maryland,4 Vicuron Pharmaceuticals, King of Prussia, Pennsylvania5

Received 17 July 2005/ Returned for modification 10 October 2005/ Accepted 22 November 2005

Anidulafungin is an echinocandin with activity against Candida species and Aspergillus species. Adult dosages under study are 50 mg/day for esophageal candidiasis and 100 mg/day for invasive candidiasis and aspergillosis. Little is known, however, about the safety and pharmacokinetics of anidulafungin in children. A multicenter, ascending-dosage study of neutropenic pediatric patients was therefore conducted. Patients were divided into two age cohorts (2 to 11 years and 12 to 17 years) and were enrolled into sequential groups to receive 0.75 or 1.5 mg/kg of body weight/day. Blood samples were obtained following the first and fifth doses. Anidulafungin was assayed in plasma, and pharmacokinetic parameters were determined. Safety was assessed using National Cancer Institute (NCI) common toxicity criteria. Pharmacokinetic parameters were determined for 12 patients at each dosage (0.75 mg/kg/day or 1.5 mg/kg/day). Concentrations and drug exposures were similar for patients between age cohorts, and weight-adjusted clearance was consistent across age. No drug-related serious adverse events were observed. One patient had fever (NCI toxicity grade of 3), and one patient had facial erythema, which resolved with slowing the infusion rate. Anidulafungin in pediatric patients was well tolerated and can be dosed based on body weight. Pediatric patients receiving 0.75 mg/kg/day or 1.5 mg/kg/day have anidulafungin concentration profiles similar to those of adult patients receiving 50 or 100 mg/day, respectively.

* Corresponding author. Mailing address: Pediatric Oncology Branch, National Cancer Institute, CRC-1-5750, 10 Center Drive, Bethesda, MD 20892. Phone: (301) 496-7103. Fax: (301) 480-2308. E-mail: walsht{at}mail.nih.gov.

Antimicrobial Agents and Chemotherapy, February 2006, p. 632-638, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.632-638.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Varisco, B. M., Benner, K. W, Prabhakaran, P. (2009). Neonatal Peritoneal Candidiasis Successfully Treated with Anidulafungin Add-On Therapy. The Annals of Pharmacotherapy 43: 1907-1910 [Abstract] [Full Text]  
  • Sucher, A. J, Chahine, E. B, Balcer, H. E (2009). Echinocandins: The Newest Class of Antifungals. The Annals of Pharmacotherapy 43: 1647-1657 [Abstract] [Full Text]  
  • Segal, B. H. (2009). Aspergillosis. NEJM 360: 1870-1884 [Full Text]  
  • Garcia-Effron, G., Park, S., Perlin, D. S. (2009). Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints. Antimicrob. Agents Chemother. 53: 112-122 [Abstract] [Full Text]  
  • Robenshtok, E., Gafter-Gvili, A., Goldberg, E., Weinberger, M., Yeshurun, M., Leibovici, L., Paul, M. (2007). Antifungal Prophylaxis in Cancer Patients After Chemotherapy or Hematopoietic Stem-Cell Transplantation: Systematic Review and Meta-Analysis. JCO 25: 5471-5489 [Abstract] [Full Text]  
  • Hope, W. W., Seibel, N. L., Schwartz, C. L., Arrieta, A., Flynn, P., Shad, A., Albano, E., Keirns, J. J., Buell, D. N., Gumbo, T., Drusano, G. L., Walsh, T. J. (2007). Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal Dosing. Antimicrob. Agents Chemother. 51: 3714-3719 [Abstract] [Full Text]  
  • Blyth, C. C., Palasanthiran, P., O'Brien, T. A. (2007). Antifungal Therapy in Children With Invasive Fungal Infections: A Systematic Review. Pediatrics 119: 772-784 [Abstract] [Full Text]  
  • Li, J. S., Eisenstein, E. L., Grabowski, H. G., Reid, E. D., Mangum, B., Schulman, K. A., Goldsmith, J. V., Murphy, M. D., Califf, R. M., Benjamin, D. K. Jr (2007). Economic Return of Clinical Trials Performed Under the Pediatric Exclusivity Program. JAMA 297: 480-488 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»